1. Home
  2. LXU vs URGN Comparison

LXU vs URGN Comparison

Compare LXU & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LSB Industries Inc.

LXU

LSB Industries Inc.

HOLD

Current Price

$15.08

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$21.46

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXU
URGN
Founded
1968
2004
Country
United States
United States
Employees
513
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
922.1M
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
LXU
URGN
Price
$15.08
$21.46
Analyst Decision
Hold
Strong Buy
Analyst Count
4
7
Target Price
$14.63
$29.29
AVG Volume (30 Days)
1.9M
619.6K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
225.93
N/A
EPS
0.34
N/A
Revenue
$615,208,000.00
$1,128,000.00
Revenue This Year
$10.78
$127.17
Revenue Next Year
N/A
$73.82
P/E Ratio
$41.62
N/A
Revenue Growth
17.77
N/A
52 Week Low
$4.92
$3.42
52 Week High
$17.22
$30.00

Technical Indicators

Market Signals
Indicator
LXU
URGN
Relative Strength Index (RSI) 56.56 61.05
Support Level $7.92 $21.40
Resistance Level $15.66 $22.29
Average True Range (ATR) 0.92 1.16
MACD -0.22 0.44
Stochastic Oscillator 49.61 81.48

Price Performance

Historical Comparison
LXU
URGN

About LXU LSB Industries Inc.

LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: